← Back to Search

Endotracheal Tube

EVAC-PU-ETT for Ventilator Acquired Pneumonia (PreVent2 Trial)

Phase 2
Waitlist Available
Led By Miriam M Treggiari, MD, PhD, MPH
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

PreVent2 Trial Summary

This trial is studying two different types of breathing tubes to see which one is better at preventing pneumonia. One of the tubes has a design feature to prevent leakage of fluids from the mouth and the back of the throat into the lower airways and lungs. The other tube is the standard tube used at most hospitals.

Eligible Conditions
  • Ventilator Acquired Pneumonia

PreVent2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive function
Quality of life
Secondary outcome measures
Airway related complications
Other outcome measures
Healthcare costs
Infection Related Ventilator-Associated Complications (IVACs)
Ventilator-Associated Events (VAEs)

PreVent2 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: EVAC-PU-ETTExperimental Treatment1 Intervention
Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
Group II: PVC-ETTActive Control1 Intervention
Polyvinylchloride endotracheal tube
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EVAC-PU-ETT
2019
Completed Phase 2
~1080

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,837 Previous Clinical Trials
2,727,339 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,814 Previous Clinical Trials
47,289,801 Total Patients Enrolled
1 Trials studying Ventilator Acquired Pneumonia
117 Patients Enrolled for Ventilator Acquired Pneumonia
Oregon Health and Science UniversityOTHER
966 Previous Clinical Trials
6,844,677 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What hazards could a patient encounter while using EVAC-PU-ETT?

"Because this is a second-stage clinical trial and there are limited safety results, EVAC-PU-ETT was assigned an assessment score of 2."

Answered by AI

Is recruitment still in progress for this experiment?

"This particular medical trial, which was initially posted on May 6th 2019 and last updated on March 7th 2022, is no longer recruiting patients. Nevertheless, there are a whopping 174 other trials that still need participants right now."

Answered by AI
~184 spots leftby Mar 2025